$YTENQ
YIELD10 BIOSCIENCE, INC.

2017 Q2 Form 10-Q Financial Statement

#000112170217000031 Filed on May 12, 2017

View on sec.gov

Income Statement

Concept 2017 Q2 2017 Q1 2016 Q1
Revenue $293.0K $324.0K $157.0K
YoY Change 55.85% 106.37% -75.66%
Cost Of Revenue $117.0K
YoY Change 39.29%
Gross Profit $40.00K
YoY Change -92.87%
Gross Profit Margin 25.48%
Selling, General & Admin $1.866M $1.276M $2.272M
YoY Change 62.4% -43.84% -7.87%
% of Gross Profit 5680.0%
Research & Development $1.140M $1.110M $1.430M
YoY Change -26.45% -22.38% -63.61%
% of Gross Profit 3575.0%
Depreciation & Amortization $60.00K $53.00K $122.0K
YoY Change -60.0% -56.56% 121.82%
% of Gross Profit 305.0%
Operating Expenses $1.866M $1.276M $2.272M
YoY Change 62.4% -43.84% -7.87%
Operating Profit -$2.711M -$2.061M -$3.543M
YoY Change 8.09% -41.83% -39.23%
Interest Expense -$20.00K -$30.00K $3.000K
YoY Change -2100.0% -1100.0% 200.0%
% of Operating Profit
Other Income/Expense, Net -$16.00K -$31.00K $3.000K
YoY Change -1700.0% -1133.33% -123.08%
Pretax Income -$2.730M -$2.090M -$3.540M
YoY Change 8.76% -40.96% -39.38%
Income Tax
% Of Pretax Income
Net Earnings -$2.730M -$2.090M -$6.500M
YoY Change -14.69% -67.85% 11.24%
Net Earnings / Revenue -931.74% -645.06% -4140.13%
Basic Earnings Per Share
Diluted Earnings Per Share -$39.00M -$29.86M -$92.86M
COMMON SHARES
Basic Shares Outstanding 28.50M shares 28.40M shares 27.37M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q2 2017 Q1 2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.000M $4.900M $5.300M
YoY Change -18.92% -7.55% -60.15%
Cash & Equivalents $3.011M $4.875M $5.271M
Short-Term Investments
Other Short-Term Assets $500.0K $500.0K $1.900M
YoY Change -54.55% -73.68% 137.5%
Inventory $420.0K
Prepaid Expenses
Receivables $213.0K $210.0K $272.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $3.908M $5.659M $8.099M
YoY Change -30.97% -30.13% -68.2%
LONG-TERM ASSETS
Property, Plant & Equipment $1.633M $1.686M $1.352M
YoY Change -36.63% 24.7% 81.97%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $95.00K $95.00K $717.0K
YoY Change -86.75% -86.75% 654.74%
Total Long-Term Assets $2.160M $2.835M $2.501M
YoY Change -42.03% 13.35% 71.65%
TOTAL ASSETS
Total Short-Term Assets $3.908M $5.659M $8.099M
Total Long-Term Assets $2.160M $2.835M $2.501M
Total Assets $6.068M $8.494M $10.60M
YoY Change -35.36% -19.87% -60.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $70.00K $51.00K $181.0K
YoY Change -95.23% -71.82% -52.86%
Accrued Expenses $2.689M $2.536M $2.654M
YoY Change 58.08% -4.45% -16.65%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.759M $2.587M $3.102M
YoY Change -31.88% -16.6% -18.67%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.100M $1.300M $322.0K
YoY Change -7.95% 303.73% 114.67%
Total Long-Term Liabilities $1.100M $1.300M $322.0K
YoY Change -7.95% 303.73% 114.67%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.759M $2.587M $3.102M
Total Long-Term Liabilities $1.100M $1.300M $322.0K
Total Liabilities $3.827M $3.933M $3.424M
YoY Change -27.04% 14.87% -13.62%
SHAREHOLDERS EQUITY
Retained Earnings -$338.2M -$335.4M -$332.3M
YoY Change 0.81% 0.96% 5.82%
Common Stock $340.5M $340.1M $339.5M
YoY Change 0.24% 0.17% 0.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.241M $4.561M $7.176M
YoY Change
Total Liabilities & Shareholders Equity $6.068M $8.494M $10.60M
YoY Change -35.36% -19.87% -60.63%

Cashflow Statement

Concept 2017 Q2 2017 Q1 2016 Q1
OPERATING ACTIVITIES
Net Income -$2.730M -$2.090M -$6.500M
YoY Change -14.69% -67.85% 11.24%
Depreciation, Depletion And Amortization $60.00K $53.00K $122.0K
YoY Change -60.0% -56.56% 121.82%
Cash From Operating Activities -$1.860M -$2.433M -$6.526M
YoY Change 70.64% -62.72% -2.03%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $161.0K
YoY Change -100.0% -100.0% 26.77%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 -$310.0K
YoY Change -100.0% -100.0%
Cash From Investing Activities $0.00 $0.00 -$468.0K
YoY Change -100.0% -100.0% 260.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -10.00K
YoY Change -96.3%
NET CHANGE
Cash From Operating Activities -1.860M -$2.433M -$6.526M
Cash From Investing Activities 0.000 $0.00 -$468.0K
Cash From Financing Activities -10.00K
Net Change In Cash -1.870M -$2.433M -$6.994M
YoY Change 19.87% -65.21% 5.0%
FREE CASH FLOW
Cash From Operating Activities -$1.860M -$2.433M -$6.526M
Capital Expenditures $0.00 $0.00 $161.0K
Free Cash Flow -$1.860M -$2.433M -$6.687M
YoY Change 116.28% -63.62% -1.49%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q1 dei Amendment Flag
AmendmentFlag
false
CY2017Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2017Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017Q1 dei Document Period End Date
DocumentPeriodEndDate
2017-03-31
CY2017Q1 dei Document Type
DocumentType
10-Q
CY2017Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001121702
CY2017Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
28498560 shares
CY2017Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2017Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2017Q1 dei Entity Registrant Name
EntityRegistrantName
YIELD10 BIOSCIENCE, INC.
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
56000 USD
CY2017Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
51000 USD
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
66000 USD
CY2017Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
210000 USD
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2702000 USD
CY2017Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2536000 USD
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
459000 USD
CY2017Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
404000 USD
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-84000 USD
CY2017Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-85000 USD
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
339527000 USD
CY2017Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
339811000 USD
CY2016Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6034700 shares
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10311316 shares
CY2016Q4 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
29622 sqft
CY2016Q4 us-gaap Assets
Assets
10748000 USD
CY2017Q1 us-gaap Assets
Assets
8494000 USD
CY2016Q4 us-gaap Assets Current
AssetsCurrent
7860000 USD
CY2017Q1 us-gaap Assets Current
AssetsCurrent
5659000 USD
CY2016Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 USD
CY2017Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12269000 USD
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5271000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7309000 USD
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4875000 USD
CY2016Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
7309000 USD
CY2017Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
4875000 USD
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28342625 shares
CY2017Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28402471 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28342625 shares
CY2017Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28402471 shares
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
283000 USD
CY2017Q1 us-gaap Common Stock Value
CommonStockValue
284000 USD
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6502000 USD
CY2017Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2093000 USD
CY2016Q1 us-gaap Costs And Expenses
CostsAndExpenses
3700000 USD
CY2017Q1 us-gaap Costs And Expenses
CostsAndExpenses
2385000 USD
CY2016Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
622000 USD
CY2017Q1 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
622000 USD
CY2012 us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
38885000 USD
CY2016Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
122000 USD
CY2017Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
53000 USD
CY2016Q1 us-gaap Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
-2958000 USD
CY2017Q1 us-gaap Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
0 USD
CY2016Q1 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic And Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare
-0.11
CY2017Q1 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic And Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare
0.00
CY2016Q3 us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
9868000 USD
CY2016Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
1000 USD
CY2017Q1 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
0 USD
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.24
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
CY2016Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-4000 USD
CY2017Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-1000 USD
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
713000 USD
CY2017Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
565000 USD
CY2016Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-3540000 USD
CY2017Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-2092000 USD
CY2016Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.13
CY2017Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.07
CY2016Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-2958000 USD
CY2017Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
0 USD
CY2016Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
71000 USD
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-5000 USD
CY2016Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
34000 USD
CY2017Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
144000 USD
CY2016Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1051000 USD
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-168000 USD
CY2016Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-10000 USD
CY2017Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 USD
CY2016Q1 us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
58000 USD
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
97000 USD
CY2017Q1 us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
-1000 USD
CY2016Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
41000 USD
CY2017Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0 USD
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-280000 USD
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2758000 USD
CY2017Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2587000 USD
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
591000 USD
CY2017Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
620000 USD
CY2016Q3 us-gaap Loss On Contract Termination
LossOnContractTermination
2641000 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
-6998000 USD
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
95000 USD
CY2017Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
95000 USD
CY2016Q1 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
307000 USD
CY2017Q1 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
0 USD
CY2016Q1 us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
-97000 USD
CY2017Q1 us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
-7000 USD
CY2016Q4 us-gaap Liabilities
Liabilities
4379000 USD
CY2017Q1 us-gaap Liabilities
Liabilities
3933000 USD
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10748000 USD
CY2017Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8494000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
-2434000 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-468000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6526000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2433000 USD
CY2016Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6498000 USD
CY2017Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2092000 USD
CY2016Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3000 USD
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-31000 USD
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3543000 USD
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2061000 USD
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
6959000 USD
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
828000 USD
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
808000 USD
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
4677000 USD
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
646000 USD
CY2016Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-4000 USD
CY2017Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-1000 USD
CY2016Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-4000 USD
CY2017Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1000 USD
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
161000 USD
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2017Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q1 us-gaap Sales Revenue Net
SalesRevenueNet
157000 USD
CY2017Q1 us-gaap Sales Revenue Net
SalesRevenueNet
324000 USD
CY2016Q4 us-gaap Security Deposit
SecurityDeposit
307000 USD
CY2016Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2272000 USD
CY2017Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1276000 USD
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1739000 USD
CY2017Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1686000 USD
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
591000 USD
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
264000 USD
CY2016Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
275000 shares
CY2017Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
275000 shares
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
6369000 USD
CY2017Q1 us-gaap Stockholders Equity
StockholdersEquity
4561000 USD
CY2017Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
363000 USD
CY2017Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
460000 USD
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
432000 USD
CY2017Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
432000 USD
CY2017Q1 us-gaap Restructuring Reserve Settled Without Cash2
RestructuringReserveSettledWithoutCash2
196000 USD
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-333357000 USD
CY2017Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-335449000 USD
CY2016Q1 us-gaap Revenue From Grants
RevenueFromGrants
157000 USD
CY2017Q1 us-gaap Revenue From Grants
RevenueFromGrants
324000 USD
CY2016Q1 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
197000 USD
CY2016Q4 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
121000 USD
CY2017Q1 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
114000 USD
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2017Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27367305 shares
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
28399811 shares
CY2016Q4 yten Accrued Commercial Manufacturing Current
AccruedCommercialManufacturingCurrent
939000 USD
CY2017Q1 yten Accrued Commercial Manufacturing Current
AccruedCommercialManufacturingCurrent
947000 USD
CY2016Q1 yten Charge For Company Common Stock Match
ChargeForCompanyCommonStockMatch
155000 USD
CY2017Q1 yten Charge For Company Common Stock Match
ChargeForCompanyCommonStockMatch
23000 USD
CY2016Q1 yten Cost Of Revenue Research And Development Expenses
CostOfRevenueResearchAndDevelopmentExpenses
1428000 USD
CY2017Q1 yten Cost Of Revenue Research And Development Expenses
CostOfRevenueResearchAndDevelopmentExpenses
1109000 USD
CY2016Q1 yten Increase Decrease In Deferred Rent And Long Term Liabilities
IncreaseDecreaseInDeferredRentAndLongTermLiabilities
-150000 USD
CY2017Q1 yten Increase Decrease In Deferred Rent And Long Term Liabilities
IncreaseDecreaseInDeferredRentAndLongTermLiabilities
-275000 USD
CY2016Q4 yten Lease Incentive Payable Noncurrent
LeaseIncentivePayableNoncurrent
1132000 USD
CY2017Q1 yten Lease Incentive Payable Noncurrent
LeaseIncentivePayableNoncurrent
1100000 USD
CY2016Q4 yten Liabilities Noncurrent Contract Termination Obligation
LiabilitiesNoncurrentContractTerminationObligation
489000 USD
CY2017Q1 yten Liabilities Noncurrent Contract Termination Obligation
LiabilitiesNoncurrentContractTerminationObligation
246000 USD
CY2017Q1 yten Operatingleaseslandlordreimbforleaseimprovementsadditionalpayments
Operatingleaseslandlordreimbforleaseimprovementsadditionalpayments
444000 USD
CY2017Q1 yten Operatingleaseslandlordreimbursementforleaseimprovements
Operatingleaseslandlordreimbursementforleaseimprovements
889000 USD
CY2017Q1 yten Period Over Which Capital Resources Are Not Sufficient To Fund Planned Operations
PeriodOverWhichCapitalResourcesAreNotSufficientToFundPlannedOperations
P12M
CY2017Q1 yten Restructuring Contract Termination Fees Payable
RestructuringContractTerminationFeesPayable
1194000 USD
CY2016Q3 yten Restructuring Target Numberof Employees Remaining
RestructuringTargetNumberofEmployeesRemaining
20 employee
CY2016 yten Sharebased Compensation Arrangementby Sharebased Payment Award Fair Value Assumptions Forfeiture Rate
SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate
0.06
CY2015Q4 yten Stock Purchase Agreement Minimum Priceper Share
StockPurchaseAgreementMinimumPriceperShare
0.50
CY2017Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents. The Company has historically invested its cash equivalents in highly rated money market funds, corporate debt, federal agency notes and U.S. treasury notes. Investments, when purchased, are acquired in accordance with the Company&#8217;s investment policy which establishes a concentration limit per issuer. At </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company&#8217;s cash equivalents are invested solely in money market funds.</font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company provides credit to customers in the normal course of business. The Company performs ongoing credit evaluations of its customers&#8217; financial condition and limits the amount of credit extended when deemed necessary.</font></div></div>
CY2017Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div>

Files In Submission

Name View Source Status
0001121702-17-000031-index-headers.html Edgar Link pending
0001121702-17-000031-index.html Edgar Link pending
0001121702-17-000031.txt Edgar Link pending
0001121702-17-000031-xbrl.zip Edgar Link pending
ex-311x20170331.htm Edgar Link pending
ex-312x20170331.htm Edgar Link pending
ex-321x20170331.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
yten-20170331.xml Edgar Link completed
yten-20170331.xsd Edgar Link pending
yten-20170331x10q.htm Edgar Link pending
yten-20170331_cal.xml Edgar Link unprocessable
yten-20170331_def.xml Edgar Link unprocessable
yten-20170331_lab.xml Edgar Link unprocessable
yten-20170331_pre.xml Edgar Link unprocessable